ESR1 and breast carcinoma: CSA’s structural similarity to estrogen and its shared binding site with 17β-estradiol and tamoxifen on ERα confer antiestrogenic properties, suggesting its potential as a novel antiestrogenic agent in breast cancer treatment [24].